MAPT and Alzheimer disease: Eighteen studies examined sex differences in biofluid markers across the AD and DLB spectrum, revealing distinct patterns in cerebrospinal fluid (CSF) and blood-based markers of neurodegeneration, tau pathology, amyloid deposition, neuroinflammation, and metabolic dysfunction.